These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

399 related articles for article (PubMed ID: 24313573)

  • 1. Temsirolimus for advanced renal cell carcinoma.
    Bergmann L; Maute L; Guschmann M
    Expert Rev Anticancer Ther; 2014 Jan; 14(1):9-21. PubMed ID: 24313573
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Temsirolimus: a safety and efficacy review.
    Bukowski RM
    Expert Opin Drug Saf; 2012 Sep; 11(5):861-79. PubMed ID: 22861825
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The clinical potential of temsirolimus in second or later lines of treatment for metastatic renal cell carcinoma.
    Stenner-Liewen F; Grünwald V; Greil R; Porta C
    Expert Rev Anticancer Ther; 2013 Sep; 13(9):1021-33. PubMed ID: 24024788
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Temsirolimus in renal cell carcinoma.
    Otto T; Eimer C; Gerullis H
    Transplant Proc; 2008 Dec; 40(10 Suppl):S36-9. PubMed ID: 19100905
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum lactate dehydrogenase predicts for overall survival benefit in patients with metastatic renal cell carcinoma treated with inhibition of mammalian target of rapamycin.
    Armstrong AJ; George DJ; Halabi S
    J Clin Oncol; 2012 Sep; 30(27):3402-7. PubMed ID: 22891270
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sunitinib, sorafenib and mTOR inhibitors in renal cancer.
    Radulovic S; Bjelogrlic SK
    J BUON; 2007 Sep; 12 Suppl 1():S151-62. PubMed ID: 17935273
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Everolimus in the treatment of renal cell carcinoma and neuroendocrine tumors.
    Chan HY; Grossman AB; Bukowski RM
    Adv Ther; 2010 Aug; 27(8):495-511. PubMed ID: 20623346
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Temsirolimus, an mTOR inhibitor for treatment of patients with advanced renal cell carcinoma.
    Malizzia LJ; Hsu A
    Clin J Oncol Nurs; 2008 Aug; 12(4):639-46. PubMed ID: 18676330
    [TBL] [Abstract][Full Text] [Related]  

  • 9. First-line Mammalian target of rapamycin inhibition in metastatic renal cell carcinoma: an analysis of practice patterns from the International Metastatic Renal Cell Carcinoma Database Consortium.
    Harshman LC; Kroeger N; Rha SY; Donskov F; Wood L; Tantravahi SK; Vaishampayan U; Rini BI; Knox J; North S; Ernst S; Yuasa T; Srinivas S; Pal S; Heng DY; Choueiri TK
    Clin Genitourin Cancer; 2014 Oct; 12(5):335-40. PubMed ID: 24787966
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Everolimus vs. temsirolimus for advanced renal cell carcinoma: use and use of resources in the US Oncology Network.
    Vogelzang NJ; Bhor M; Liu Z; Dhanda R; Hutson TE
    Clin Genitourin Cancer; 2013 Jun; 11(2):115-20. PubMed ID: 23063578
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral and intravenously administered mTOR inhibitors for metastatic renal cell carcinoma: pharmacokinetic considerations and clinical implications.
    Danesi R; Boni JP; Ravaud A
    Cancer Treat Rev; 2013 Nov; 39(7):784-92. PubMed ID: 23375248
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanisms of Disease: survival benefit of temsirolimus validates a role for mTOR in the management of advanced RCC.
    Figlin RA
    Nat Clin Pract Oncol; 2008 Oct; 5(10):601-9. PubMed ID: 18607393
    [TBL] [Abstract][Full Text] [Related]  

  • 13. mTOR pathway inhibition in renal cell carcinoma.
    Pinto Marín A; Redondo Sánchez A; Espinosa Arranz E; Zamora Auñón P; Castelo Fernández B; González Barón M
    Urol Oncol; 2012; 30(4):356-61. PubMed ID: 20207176
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activity of single-agent bevacizumab in patients with metastatic renal cell carcinoma previously treated with vascular endothelial growth factor tyrosine kinase inhibitors.
    Turnbull JD; Cobert J; Jaffe T; Harrison MR; George DJ; Armstrong AJ
    Clin Genitourin Cancer; 2013 Mar; 11(1):45-50. PubMed ID: 23041453
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The combination of bevacizumab/temsirolimus after first-line anti-VEGF therapy in advanced renal-cell carcinoma: a clinical and biomarker study.
    Bamias A; Karavasilis V; Gavalas N; Tzannis K; Samantas E; Aravantinos G; Koutras A; Gkerzelis I; Kostouros E; Koutsoukos K; Zagouri F; Fountzilas G; Dimopoulos MA
    Int J Clin Oncol; 2019 Apr; 24(4):411-419. PubMed ID: 30374686
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metastatic clear cell renal carcinoma - an unusual response to Temsirolimus in second line therapy.
    Stanculeanu DL; Lazescu A; Zob DD; Bunghez R; Anghel R; Poteca TD
    J Med Life; 2016; 9(2):193-8. PubMed ID: 27453754
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.
    Hudes G; Carducci M; Tomczak P; Dutcher J; Figlin R; Kapoor A; Staroslawska E; Sosman J; McDermott D; Bodrogi I; Kovacevic Z; Lesovoy V; Schmidt-Wolf IG; Barbarash O; Gokmen E; O'Toole T; Lustgarten S; Moore L; Motzer RJ;
    N Engl J Med; 2007 May; 356(22):2271-81. PubMed ID: 17538086
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment outcome with mTOR inhibitors for metastatic renal cell carcinoma with nonclear and sarcomatoid histologies.
    Voss MH; Bastos DA; Karlo CA; Ajeti A; Hakimi AA; Feldman DR; Hsieh JJ; Molina AM; Patil S; Motzer RJ
    Ann Oncol; 2014 Mar; 25(3):663-668. PubMed ID: 24458473
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimal treatment of poor-risk renal cell carcinoma patients with mTOR inhibitors and anti-VEGFR agents.
    Coinu A; Petrelli F; Barni S
    Expert Rev Anticancer Ther; 2016; 16(1):33-43. PubMed ID: 26535485
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sequential mTOR inhibitor treatment with temsirolimus in metastatic renal cell carcinoma following failure of VEGF receptor tyrosine kinase inhibitors.
    Weikert S; Kempkensteffen C; Busch J; Johannsen M; Grünwald V; Zimmermann K; Flörcken A; Westermann J; Weinkauf L; Miller K; Keilholz U
    World J Urol; 2013 Aug; 31(4):805-9. PubMed ID: 21512806
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.